263 related articles for article (PubMed ID: 23702225)
1. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
Pałasz A; Lapray D; Peyron C; Rojczyk-Gołębiewska E; Skowronek R; Markowski G; Czajkowska B; Krzystanek M; Wiaderkiewicz R
Int J Neuropsychopharmacol; 2014 Jan; 17(1):157-68. PubMed ID: 23702225
[TBL] [Abstract][Full Text] [Related]
2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
5. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
6. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
7. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
[TBL] [Abstract][Full Text] [Related]
8. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
9. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
10. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
11. Suvorexant: something new for sleep?
Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
[TBL] [Abstract][Full Text] [Related]
12. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
Herring WJ; Roth T; Krystal AD; Michelson D
J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
[TBL] [Abstract][Full Text] [Related]
13. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice.
Roundtree HM; Simeone TA; Johnson C; Matthews SA; Samson KK; Simeone KA
Sleep; 2016 Feb; 39(2):357-68. PubMed ID: 26446112
[TBL] [Abstract][Full Text] [Related]
14. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
[No Abstract] [Full Text] [Related]
15. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
16. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
17. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.
Yao L; Ramirez AD; Roecker AJ; Fox SV; Uslaner JM; Smith SM; Hodgson R; Coleman PJ; Renger JJ; Winrow CJ; Gotter AL
J Neurochem; 2017 Jul; 142(2):204-214. PubMed ID: 28444767
[TBL] [Abstract][Full Text] [Related]
18. Prescription Drugs Used in Insomnia.
Dujardin S; Pijpers A; Pevernagie D
Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
[TBL] [Abstract][Full Text] [Related]
19. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.
Tannenbaum PL; Tye SJ; Stevens J; Gotter AL; Fox SV; Savitz AT; Coleman PJ; Uslaner JM; Kuduk SD; Hargreaves R; Winrow CJ; Renger JJ
Sleep; 2016 Mar; 39(3):603-12. PubMed ID: 26943466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
